DrugPatentWatch Database Preview
Ucb Inc Company Profile
What is the competitive landscape for UCB INC, and what generic alternatives to UCB INC drugs are available?
There are fifteen US patents protecting UCB INC drugs.
There are three hundred and thirty patent family members on UCB INC drugs in forty-nine countries and thirty-eight supplementary protection certificates in eleven countries.
Summary for Ucb Inc
| International Patents: | 330 |
| US Patents: | 15 |
| Tradenames: | 27 |
| Ingredients: | 22 |
| NDAs: | 40 |
| Drug Master File Entries: | 1 |
| Patent Litigation for Ucb Inc: | See patent lawsuits for Ucb Inc |
Drugs and US Patents for Ucb Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | VIMPAT | lacosamide | TABLET;ORAL | 022253-004 | Oct 28, 2008 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Ucb Inc | BRIVIACT | brivaracetam | SOLUTION;INTRAVENOUS | 205837-001 | May 12, 2016 | RX | Yes | Yes | 6,784,197 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Ucb Inc | PARCOPA | carbidopa; levodopa | TABLET, ORALLY DISINTEGRATING;ORAL | 076699-003 | Aug 27, 2004 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-002 | Oct 30, 2003 | DISCN | No | No | 6,221,392 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Ucb Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | VIMPAT | lacosamide | TABLET;ORAL | 022253-001 | Oct 28, 2008 | 5,654,301 | ➤ Sign Up |
| Ucb Inc | UNIRETIC | hydrochlorothiazide; moexipril hydrochloride | TABLET;ORAL | 020729-002 | Jun 27, 1997 | 4,743,450 | ➤ Sign Up |
| Ucb Inc | KEPPRA | levetiracetam | TABLET;ORAL | 021035-003 | Nov 30, 1999 | 4,837,223 | ➤ Sign Up |
| Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-001 | Oct 30, 2003 | 6,221,392 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for UCB INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg, 0.5 mg, 1 mg and 2 mg | ➤ Subscribe | 2005-12-27 |
| ➤ Subscribe | Tablets | 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg | ➤ Subscribe | 2004-01-15 |
| ➤ Subscribe | Tablets | 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2012-10-29 |
| ➤ Subscribe | Extended-release Transdermal Film | 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr | ➤ Subscribe | 2013-11-26 |
| ➤ Subscribe | Tablets | 1000 mg | ➤ Subscribe | 2007-01-24 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2012-10-29 |
| ➤ Subscribe | Extended-release Tablets | 1000 mg | ➤ Subscribe | 2011-01-07 |
| ➤ Subscribe | Injection | 10 mg/mL, 20 mL | ➤ Subscribe | 2016-06-30 |
Non-Orange Book US Patents for Ucb Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,692,028 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | ➤ Sign Up |
| 6,858,740 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | ➤ Sign Up |
| 6,713,635 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | ➤ Sign Up |
| 7,863,316 | Extended release formulation of Levetiracetam | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Ucb Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Israel | 170181 | ➤ Sign Up |
| Israel | 166768 | ➤ Sign Up |
| European Patent Office | 1265862 | ➤ Sign Up |
| European Patent Office | 1033978 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Ucb Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0025 | France | ➤ Sign Up | PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215 |
| 2006 00020 | Denmark | ➤ Sign Up | PRODUCT NAME: ROTIGOTINE |
| 00095 | Netherlands | ➤ Sign Up | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
| 1033978/01 | Switzerland | ➤ Sign Up | TEILUEBERTRAGUNG |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
